-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3573 A Pragmatic Monitoring Model for Non-Relapse Mortality Risk Based on Machine Learning in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation

Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
Hematology Disease Topics & Pathways:
Research, Translational Research, Technology and Procedures, Human, Machine learning, Serologic Tests
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Yang-Liu Shao1*, Jingjing Yang1*, Xiaobo Li2*, Di Guan2*, Xiawei Zhang1*, Wu Tong3*, Zeliang Song4*, Dao Wang5*, Zhijie Wei6*, Jingbo Wang7*, Xiangjun Liu, PhD2*, Yuelin He, MD8*, Liping Dou, MD1 and Daihong Liu, MD9*

1The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
2Beijing BFR Gene Diagnostics LTD., Beijing, China
3Department of Bone Marrow Transplantation, Beijing GoBroad Boren Hospital, Beijing, China
4Department of Pediatric Hematology, Children’s Hospital, Beijing, China
5Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
6Beijing Lu Daopei Hospital, Beijing, China
7Aerospace Center Hospital, Beijing, China
8Department of Pediatrics, Nanfang Hospital, Guangzhou, China
9Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China

Background:Prognostic biomarkers play a crucial role in assessing non-relapse mortality (NRM) following allogeneic hematopoietic stem cell transplantation (allo-HSCT).The concentrations of biomarkers fluctuate with the progression of complications and corresponding clinical interventions. However current predictive models are commonly built and applied based on biomarker concentrations measured at a single fixed time point, which may limit their predictive validity and utility for clinical applications.

Methods: A prospective, multicenter study (NCT04284904) involved 621 allo-HSCT patients from 7 Chinese transplant centers. Concentrations of biomarkers (ST2, REG3α, TNFR1, IL6, and IL8) were measured at day 7/14/28/60/90 post-HSCT; patients with acute GVHD were monitored at onset and weekly during the first treatment month.The time point of relative maximum concentration for each patient (MC) was determined based on the time at which the maximum metric was reached. A pragmatic monitoring model employing the relative maximum concentrations of ST2 and TNFR1 within three months post-transplantation was developed to forecast 6-month NRM in allo-HSCT patients: log10[-log10(1 - p)] = 1.4798(log10ST2) + 3.2733(log10TNFR1) - 21.632,where p = predicted probability of 6-month NRM.

Results:The 460 patients in the modeling cohort were randomly split into a training (n=310) and a test (n=150) set, with model validation performed on an independent cohort (n=159). In both the modeling and validation cohorts, the combination of ST2 and TNFR1 exhibited the highest AUC and C-index among the models (training set: 0.85, 0.80 ; test set: 0.85, 0.80; validation set: 0.95, 0.93). Patients were categorized into three risk groups based on model-derived thresholds: low risk (LR, ≤0.0567), moderate risk (MR, 0.0567–0.1309), and high risk (HR, ≥0.1309). The HR group experienced significantly higher 6-month NRM than the MR and LR groups in both the modeling cohort (40.62% vs. 13.11% vs. 1.57%, P < 0.001) and the validation cohort (47.37% vs. 9.76% vs. 0.00%; P < 0.001). Further, our investigation revealed that our predictive model effectively gauged NRM risk independently of HLA matching, recipient age, donor type, ATG-based GVHD prophylaxis, and other clinical considerations. Multivariate analysis identified model score as significant NRM predictors (P < 0.0001). The model consistently identified high-risk NRM patients throughout post-HSCT time points. The model effectively stratifies NRM risk in patients with or without acute GVHD.

Conclusions: A pragmatic monitoring model for predicting NRM in allo-HSCT patients was established, showing potential for identifying high-risk individuals and improving personalized treatment.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH